EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis

Yuval Zolotov iD, Deepika E Slawek iD, Chenshu Zhang, Jonathan Ross iD, Frances R Levin, Stephen Dahmer, Chinazo O Cunningham, Joanna L Starrels iD, Julia H Arnsten iD, Nancy L Sohler

Substance Use & Addiction Journal · 20.11.2026

DOI: 10.1177/29767342261496711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Substance Use & Addiction Journal, online erschienen am 20.11.2026. Verfasst von Yuval Zolotov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Systems Management, Faculty of Health Sciences, Ariel University, Israel. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute on Drug Abuse, National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Given the scarce data on adverse outcomes in people who use medical cannabis, the objective of this study was to assess the prevalence of adverse outcomes, including cannabis use disorder (CUD), opioid use disorder (OUD), hazardous alcohol use, cannabis diversion, cannabis-related injuries, and emergency room visits in individuals newly certified for medical cannabis for chronic pain in New York.

Methods

In an 18-month longitudinal cohort study, data were collected from 223 adults (mean age = 56.3 years, 54.3% female). At baseline and every 3 months, we assessed study outcomes using structured DSM-5 diagnostic interviews, standardized questionnaires, and study-specific questions. Medical and unregulated cannabis use were self-reported separately every 2 weeks via web surveys.

Findings

Over 18 months, 4.9% of participants met the DSM-5 criteria for CUD at 1 or more study visits, 0.9% for OUD, 6.7% for hazardous alcohol use, 4.0% for cannabis diversion, and 1.8% for cannabis-related injuries. The mean frequency of medical and unregulated cannabis use per 2-week period was 9.6 and 5.3 days, respectively, for those with CUD and 6.4 and 2.7 days, respectively, for those without CUD. No consistent patterns emerged for other adverse outcomes.

Conclusions

In this cohort of adults with chronic pain newly certified for medical cannabis, adverse outcomes were infrequent during the 18-month follow-up, despite participants reporting regular use throughout the study. However, these findings should be interpreted with caution, as larger or longer term studies may detect risks not captured in this study. Continued patient education and monitoring remain important, and more research is needed to understand the long-term safety of medical cannabis use, particularly as policies continue to evolve.

Schlagwörter

Stichwörter der Autor:innen

adverse outcomescannabis use disorderdiversionmedical cannabismedical marijuana

Autor:innen und Institutionen

  • Department of Health Systems Management, Faculty of Health Sciences, Ariel University, Israel.
  • Division of General Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
  • Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
  • Andrew Weil Center for Integrative Medicine, The University of Arizona, Tucson, AZ, USA.
  • New York State Office of Addiction Services and Supports, Albany, NY, USA.
  • CUNY School of Medicine, City University of New York, NY, USA.

ORCID-Profile: Yuval Zolotov, Deepika E Slawek, Jonathan Ross, Joanna L Starrels, Julia H Arnsten

Förderung

  • National Institute on Drug Abuse
  • National Institute of Mental Health

Zitieren

APA

Zolotov, Y., Slawek, D. E., Zhang, C., Ross, J., Levin, F. R., Dahmer, S., Cunningham, C. O., Starrels, J. L., Arnsten, J. H., & Sohler, N. L. (2026). Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis. Substance Use & Addiction Journal. https://doi.org/10.1177/29767342261496711

Vancouver

Zolotov Y, Slawek DE, Zhang C, Ross J, Levin FR, Dahmer S, et al. Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis. Substance Use & Addiction Journal. 2026. doi:10.1177/29767342261496711

BibTeX
@article{Zolotov2026,
  author = {Zolotov, Yuval and Slawek, Deepika E and Zhang, Chenshu and Ross, Jonathan and Levin, Frances R and Dahmer, Stephen and Cunningham, Chinazo O and Starrels, Joanna L and Arnsten, Julia H and Sohler, Nancy L},
  title = {Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis},
  journal = {Substance Use & Addiction Journal},
  year = {2026},
  doi = {10.1177/29767342261496711}
}
Kostenlos starten →